A Single-Center, Randomized, Open-Label, 2-Period Complete Crossover Study to Compare the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 27 May 2016
At a glance
- Drugs LGD 6972 (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Ligand Pharmaceuticals
- 17 May 2016 Status changed from active, no longer recruiting to completed.
- 05 May 2016 Planned End Date changed from 1 May 2016 to 1 Jun 2016.
- 05 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 May 2016.